Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.
Schoolwerth
A C
AC
Sica
D A
DA
Ballermann
B J
BJ
Wilcox
C S
CS
D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000572:American Heart Association; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000075202:Contraindications; D019468:Disease Management; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects*; D010953:Plasma Volume; D006435:Renal Dialysis; D012307:Risk Factors; D013903:Thoracic Surgery
D000806:Angiotensin-Converting Enzyme Inhibitors